CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
Astraveus is developing a microfluidic chip to enhance Chimeric Antigen Receptor T-cell therapies by significantly reducing production costs and improving treatment quality. Their prototype system, Lakhesys, automates the production process, aiming to make these cancer treatments more accessible to patients.
Chimeric Antigen Receptor T-cell therapies (‘CAR-T’) are ushering in an incredibly exciting era of using a patient’s own cells to cure their cancer.
The prospect of using a patient’s own cells to cure their disease is theoretically limitless.
However, with all of this excitement comes a shadow.
The cost of these life-saving treatments is currently so prohibitive that it threatens to put extreme cost-pressure on healthcare providers globally in the years ahead.Astraveus has developed a highly…
ASTRAVEUS SAS
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
